What is Amici Pharmaceuticals?
Amici Pharmaceuticals, headquartered in Melville, N.Y., operates as a generics firm specializing in the acquisition and development of niche pharmaceutical products. Leveraging a robust network of development and manufacturing partners, the company has built a portfolio that includes ophthalmic and oral solid dosage forms. Amici Pharmaceuticals places a strong emphasis on customer service and ensures its finished products are manufactured in facilities adhering to generally accepted good manufacturing practices. A recent product launch, metolazone tablets, a generic equivalent of Zaroxolyn, offers a treatment for fluid and salt retention, commonly associated with conditions like congestive heart failure and renal diseases. The product is available in 2.5 mg, 5 mg, and 10 mg dosage strengths.
How much funding has Amici Pharmaceuticals raised?
Amici Pharmaceuticals has raised a total of $83K across 1 funding round:
Debt
$83K
Debt (2021): $83K with participation from PPP
What's next for Amici Pharmaceuticals?
With the recent capital infusion, Amici Pharmaceuticals is poised to accelerate its strategic objectives. The company's focus on acquiring and developing niche products, particularly in the generics space, suggests a strategy aimed at capturing specific market segments with high demand and limited competition. Future growth is likely to involve expanding its product pipeline, potentially through further acquisitions or strategic partnerships, and enhancing its distribution channels to reach a broader patient base. The company's commitment to quality manufacturing and customer service will remain a cornerstone of its expansion efforts.
See full Amici Pharmaceuticals company page
